Regulatory

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

Pharmaceutical Technology

The EMA's CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

Regulatory Read full story

pharminent April 24, 2026 (Last updated: April 24, 2026)

Pharmaceutical Technology

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

Regulatory Read full story